68 results about "Enalapril" patented technology

Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.

The present invention relates to findings that reducing the activity of Plasminogen Activator Inhibitor-1 (PAI-1) suppresses an excessive deposition of collagen which is known as a cause for the formation of abnormal scars. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, skin disfiguring conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by an excessive deposit of collagen in a wound healing process. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease an excessive accumulation of collagen, prevent the formation of an abnormal scar, and / or treat abnormal scars that result from an excessive accumulation of collagen. The PAI-1 activity can be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine based compounds, tetramic acid based compounds, hydroxyquinolinone based compounds, Enalapril, Eprosartan, Troglitazone, Vitamin C, Vitamin E, Mifepristone (RU486), and Spironolactone to name a few. Another aspect of the present invention is directed to methods of measuring PAI-1 activity in a wound healing process and determining the propensity of the formation of an abnormal scar.

The invention relates to a compound preparation containing enalapril for treating hypertension, comprising main compositions and a matched pharmaceutically acceptable vector, wherein the main compositions include L-amlodipine or a pharmaceutically acceptable salt of the L-amlodipine, hydrochlorothiazide and the enalapril or other pharmaceutically acceptable salt of the enalapril, and the L-amlodipine or the pharmaceutically acceptable salt of the L-amlodipine is contained in each preparation unit. According to an action mechanism that drug combination fully fulfills the function of drug complementarity, the invention increases the curative effect, rapidly reaches the standard with the blood pressure standard-reaching rate of 82 percent, reduces the adverse reaction relative to the increase of a certain dosage and keeps longer action time. The compound preparation has the advantages of fast effect, high blood pressure standard-reaching rate, little side effect and low cost.

The present invention provides a method for treatment of diabetes, comprising administering a pitavastatin, and in combination therewith, enalapril or a salt thereof.